Nearly 37% of the senior-level jobs at cannabis companies are held by women, according to a Marijuana Business Daily survey. Although the number of women holding top spots has vacillated since 2015, the percentage of women top executives in the cannabis space is still...
This has been a roller-coaster year for cannabis stocks, a signal that investors are assessing the opportunity more critically than they have before.
This has been a roller-coaster year for cannabis stocks, a signal that investors are assessing the opportunity more critically than they have before.
Marijuana Business Daily hired two equity research analysts to expand its coverage for investors in the cannabis space. Craig Behnke and Mike Regan will develop and oversee content for MJBizDaily's Investor Intelligence product. Both analysts...
Curaleaf continued its march to become a truly national cannabis company with its $875 million acquisition of Grassroots, one of the largest private multistate operators (MSO) in the United States.
As support for federal U.S. cannabis reform continues to build, institutional investors are taking notice – and once they make the leap, investors already in the space are well positioned to reap the rewards.
Biosynthesis – the mass production of specific cannabinoids in a lab setting – might be setting up to be the next big disruptor for the cannabis industry.
Since most businesses are purchased as a multiple of earnings (expressed as earnings before interest, taxes, depreciation and amortization, or EBITDA), the seller has substantial motivation to get those earnings as high as possible before putting the company up for...
The focus on earnings is a normal function of everyday operations for any successful business. However, since every dollar added to EBITDA can bring back a substantial return in valuation through a sale – often 7X, 8X or higher- sellers are particularly eager to put dollars on the EBITDA line, especially in the trailing 12 months before a sale.
If we are investing in companies, there is only one bet we are making – and it’s on humans.
The cannabis industry changes at a rapid clip - and that means it can be challenging to get data and unbiased analysis that keeps pace. That's why, starting this month, you're seeing an enhanced Investor Intelligence. Based on your feedback and insights, we've...
There is a fallacy in investing - especially in cannabis investing - that we bet on a founder’s idea. So, in cannabis, we bet on the number of acres cultivated, the list of licenses, the pounds sold, the THC content, etc. Yet, the truth of it is, if we are investing...
